

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 July 2020 (16.07.2020)



(10) International Publication Number
WO 2020/146822 A1

(51) International Patent Classification:

A61K 31/428 (2006.01) C07D 277/62 (2006.01)
A61K 31/12 (2006.01) C07D 277/68 (2006.01)
A61K 31/426 (2006.01)

(21) International Application Number:

PCT/US2020/013217

(22) International Filing Date:

10 January 2020 (10.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/791,641 11 January 2019 (11.01.2019) US

(71) Applicant: **NAEGIS PHARMACEUTICALS INC.**
[CA/CA]; 720, 999 West Broadway, Vancouver, British
Columbia V5Z 1K5 (CA).

(72) Inventors: **BURGOYNE, David, L.**; 4715 53A Street,
Delta, British Columbia V4K 3V4 (CA). **DEBRUIN, Erin**;
1819 Langan Ave, Port Coquitlam, British Columbia V3C
5K3 (CA). **FONAREV, Julia**; #61 - 3900 Moresby Dr.,
Richmond, British Columbia V7C 4G6 (CA). **YEE, James,
Gee, Ken**; 329 Mount Royal Drive, Port Moody, British
Columbia V3H 1R3 (CA). **LANGLANDS, John, Michael**;
#225 - 12931 Railway Avenue, Richmond, British Colum-
bia V7E 6M5 (CA).

(74) Agent: **PARKER, David, W.**; BioMed IP, 2400 NW 80th
Street, PMB 138, Seattle, Washington 98117 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: LEUKOTRIENE SYNTHESIS INHIBITORS




FIG. 4A

(57) Abstract: Provided are specific leukotriene synthesis inhibitor compounds and pharmaceutical compositions comprising the compounds and methods of using the compounds and the pharmaceutical compositions in treating, for example, inflammatory diseases or conditions.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*